Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

As with other drugs, Darzalex Faspro (daratumumab/hyaluronidase-fihj) can cause side effects, such as upper respiratory tract infection. If you’re not able to ...

The company's best-known drug, Darzalex (or daratumumab), was developed in partnership with Johnson & Johnson for multiple myeloma. Darzalex is entrenched in multiple myeloma care for several ...

Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

The company's flagship product, Darzalex, has been a major revenue driver, but the company is now working to diversify its portfolio and prepare for the post-Darzalex era. Want deeper insights ...

Darzalex & Darzalex Faspro are indicated for the treatment of multiple myeloma. Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields ...

Most products closed the year strong with Darzalex royalties leading the way. Epkinly net sales were $78 million, and this was slightly lower than expected due to one-time adjustments in France ...

Its key product, Darzalex, is responsible for a majority of its revenue. Recent strategic actions include leveraging partnerships and investing heavily in research and development to expand its ...